Journal of the International Association of Providers of AIDS Care (Mar 2014)

Characteristics and Factors Associated with the Clinical Forms of Lipoatrophy during Highly Active Antiretroviral Therapy in Ouagadougou, Burkina Faso

  • Oumar Guira MD,
  • Hervé Tiéno MD,
  • Bertille Yaméogo MD,
  • Arnaud Eric Diendéré MD,
  • Nina Korsaga MD,
  • Yempabou Sagna MD,
  • Lassané Zoungrana MD,
  • Ismael Diallo MD,
  • René Traoré MD,
  • Joseph Youssouf Drabo MD

DOI
https://doi.org/10.1177/2325957413503369
Journal volume & issue
Vol. 13

Abstract

Read online

Background: We aimed to study the factors associated with clinical forms of lipoatrophy in patients receiving highly active antiretroviral therapy (HAART) in Yalgado Ouédraogo Teaching Hospital, Ouagadougou, Burkina Faso. Methods: This cross-sectional review from March 10 to November 10, 2011, included a nonprobability sample of HIV-infected adults receiving antiretroviral (ARV) medications for at least 6 months and monitored in the internal medicine department. The diagnosis of lipoatrophy was clinical. Results: Three hundred patients were included. The sex ratio was 0.4 and the mean age was 42.1 ± 8.5 years. The mean duration of HAART was 73.2 ± 30.9 months. In all, 97 (32.3%) patients had lipoatrophy: 75 (25%) isolated and 22 (7.3%) mixed syndrome. Facial lipoatrophy was frequent (61.8%). Isolated lipoatrophy was associated with male sex ( P = .002) and body mass index ≤25 ( P 42 years ( P < .05), physical activity ( P = .003), smoking ( P = .001), stavudine (d4T; P = .0001), or protease inhibitors ( P = .01). Conclusion: Prevention of lipoatrophy associated with HAART requires the exclusion of modifiable risk factors that we identified.